LON:DPH Dechra Pharmaceuticals (DPH) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Dechra Pharmaceuticals Stock (LON:DPH) Get Dechra Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2.04 million shsAverage Volume1.29 million shsMarket Capitalization£4.40 billionP/E RatioN/ADividend Yield1.20%Price TargetN/AConsensus RatingN/A Company Overview Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom. Read More Receive DPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DPH Stock News HeadlinesVeterinary drug firm Dechra will move global HQ to Boston this summerMarch 11, 2026 | bostonglobe.comBDechra Pharmaceuticals PLC (DPH.L)February 15, 2024 | finance.yahoo.comYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 24 at 1:00 AM | Profits Run (Ad)Dechra Pharmaceuticals Stock (OTC:DPHAY) Dividends: History, Yield and DatesFebruary 11, 2024 | benzinga.comForm 8.3 - Dechra Phartmaceuticals PLC - AmendmentJanuary 15, 2024 | finance.yahoo.comUK's Hargreaves says Dechra's Platt to succeed Oppenheimer as chairNovember 29, 2023 | msn.comForm 8.3 - DPH LN Equity 09-November-23 Decrease in Traded Position DisclosureNovember 10, 2023 | finance.yahoo.comDechra Pharmaceuticals PLC DPHNovember 9, 2023 | morningstar.comMSee More Headlines DPH Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Dechra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dechra Pharmaceuticals investors own include AstraZeneca (AZN), Barratt Developments (BDEV), JD Sports Fashion (JD), Rolls-Royce Holdings plc (RR.L), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY) and Glencore (GLEN). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:DPH CIKN/A Webwww.dechra.com Phone+44-1606-814730FaxN/AEmployees2,457Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth1.42Net Income-£27.90 million Net Margins-3.66% Pretax MarginN/A Return on Equity-3.92% Return on Assets0.75% Debt Debt-to-Equity Ratio66.80 Current Ratio2.85 Quick Ratio1.66 Sales & Book Value Annual Sales£761.50 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.43 Book ValueGBX 663 per share Price / BookN/AMiscellaneous Outstanding Shares113,910,000Free FloatN/AMarket Cap£4.40 billion OptionableNot Optionable Beta0.78 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (LON:DPH) was last updated on 1/16/2024 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dechra Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Dechra Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
